A biotech company developing an AI-assisted cell-reprogramming platform
Beijing, ChinaBiotech
| Round | Amount | Announced | Lead | Verified | Status | Sources |
|---|---|---|---|---|---|---|
| Seed Seed | n/a | ~ 2026-09-22 | not stated | 1 | [ CHECK ] | 1 |
[ VERIFIED ]0.56 read against 1 source
[ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]1 page read: techstartups.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]confirmedread back across 1 source·[ BRANDING ]homepage not matched·[ AGENT ]dossier built by the Firecrawl agent | ||||||
ZhiYin Bio builds an AI-assisted cell-reprogramming platform for developing oncology immunotherapies and regenerative-medicine products.
ZhiYin Bio is targeting problems the coverage identifies in conventional gene editing and cell engineering, including genomic-safety risks, weak solid-tumor efficacy, high autologous-therapy costs, and long manufacturing cycles, with an iCellFate platform that reprograms cell identity and state through epigenetic regulation without changing DNA sequences. Its seed financing of tens of millions of RMB, led exclusively by Shaanxi Growth Fund, is earmarked for preclinical work, IND applications, GMP-lab construction, and equipment as it advances NKaT oncology and regenerative-medicine programs toward clinical translation.
No homepage passed the identity check, so nothing was written. Refresh profile tries again with what the record now knows.
None named.